Lucy Codrington News Today

(Bloomberg) — Roche Holding AG cut a fifth of its pipeline of experimental drugs in recent quarters as its new chief executive tries to revive growth after a series of research setbacks.  Trimmed so far this year were a trio of cancer projects and an experimental psychiatric compound, Roche said on Wednesday as it reported…

Company entered obesity drug race last year but its experimental pill remains in early-stage tests

With a market capitalization of 4 billion dollars, Zealand Pharma, a Danish biotech founded in 1998 that also operates in the USA, is aiming to enter the highly lucrative anti-obesity drugs market. In... -January 24, 2024 at 10:14 am EST - MarketScreener

(Bloomberg) -- A new cancer medicine developed by AstraZeneca Plc and Daiichi Sankyo Co. seemed to fall short of investors’ expectations in partial results released early after a data leak at a medical conference. Most Read from BloombergBiden Vows Aid for Gaza, Backs Israel Over Hospital BlastHospital Blast Kills Hundreds as Israel, Hamas Trade BlameStocks Drop, Oil Climbs on Renewed Mideast Risks: Markets WrapUPenn Donors Pile Pressure on School as David Magerman Pulls SupportIsrael Lat...

Here are some of the stocks and sectors that are likely to see the biggest impact from the boom in demand for weight-loss drugs. Read on.

Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the